Mallinckrodt Plc (MNK)

22.09
NYSE : Health Technology
Prev Close 23.80
Day Low/High 22.08 / 23.65
52 Wk Low/High 11.65 / 36.65
Avg Volume 1.90M
Exchange NYSE
Shares Outstanding 83.50M
Market Cap 1.99B
EPS -42.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mallinckrodt's Hobart, N.Y. And St. Louis, Mo. Sites Recognized As 2019 Manufacturing Leadership Award Winners

Mallinckrodt's Hobart, N.Y. And St. Louis, Mo. Sites Recognized As 2019 Manufacturing Leadership Award Winners

-- Hobart site honored for second year in a row, recognized this year for talent management leadership -

Mallinckrodt Presents New Data On Real-World Resource Utilization Associated With Continuation Of Systemic Treatment Among Patients With Cutaneous T-cell Lymphoma At 2019 American Academy Of Dermatology Annual Meeting

Mallinckrodt Presents New Data On Real-World Resource Utilization Associated With Continuation Of Systemic Treatment Among Patients With Cutaneous T-cell Lymphoma At 2019 American Academy Of Dermatology Annual Meeting

-- Retrospective study analyzed the relationship between continued systemic treatment and various healthcare resources and costs such as ER costs, ER visits, hospitalizations, and total inpatient days --

Notable Tuesday Option Activity: MNK, DDS, RRGB

Notable Tuesday Option Activity: MNK, DDS, RRGB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Mallinckrodt plc , where a total volume of 25,509 contracts has been traded thus far today, a contract volume which is representative of approximately 2.6 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 212.6% of MNK's average daily trading volume over the past month, of 1.2 million shares.

Mallinckrodt Plc Reports Strong Fourth Quarter And Total Company 2018 Results, Announces 2019 Guidance And Strategic Priorities

Mallinckrodt Plc Reports Strong Fourth Quarter And Total Company 2018 Results, Announces 2019 Guidance And Strategic Priorities

STAINES-UPON-THAMES, United Kingdom, Feb. 26, 2019 /PRNewswire/ -- Fourth quarter net sales of $834.

Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG

Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG

-- Collaboration with experts in photopheresis field expected to further enhance understanding of photopheresis' effect on immune modulation across a range of severe and critical conditions --

Short-Selling Is Really Hard. Just Ask Citron Research

Short-Selling Is Really Hard. Just Ask Citron Research

Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.

Mallinckrodt Announces Interim Analysis Results For Therakos® Platform Phase 3 Clinical Trial In Treatment Of Pediatric Patients With Steroid Refractory Acute Graft-versus-Host Disease

Mallinckrodt Announces Interim Analysis Results For Therakos® Platform Phase 3 Clinical Trial In Treatment Of Pediatric Patients With Steroid Refractory Acute Graft-versus-Host Disease

-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol --

Mallinckrodt To Present At Barclays Global Healthcare Conference

Mallinckrodt To Present At Barclays Global Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Feb. 12, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, March 12, 2019, at Barclays Global Healthcare Conference at the Loews...

Interesting MNK Put And Call Options For March 29th

Interesting MNK Put And Call Options For March 29th

Investors in Mallinckrodt plc saw new options begin trading today, for the March 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new March 29th contracts and identified one put and one call contract of particular interest.

Mallinckrodt Provides Update On Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial In Patients With Rheumatoid Arthritis (RA)

Mallinckrodt Provides Update On Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial In Patients With Rheumatoid Arthritis (RA)

-- Open-label phase of study completed; primary end point results consistent¹ with prior reports (n=116) that showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks --

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Mallinckrodt Plc To Report Earnings Results For Fourth Quarter And Fiscal 2018

Mallinckrodt Plc To Report Earnings Results For Fourth Quarter And Fiscal 2018

STAINES-UPON-THAMES, United Kingdom, Jan. 14, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, announced today that it will report fourth quarter and fiscal 2018 earnings results for the...

March 1st Options Now Available For Mallinckrodt (MNK)

March 1st Options Now Available For Mallinckrodt (MNK)

Investors in Mallinckrodt plc saw new options become available today, for the March 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new March 1st contracts and identified one put and one call contract of particular interest.

Data On Use Of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) In Patients With Rare Cause Of Nephrotic Syndrome Published In Transplantation

Data On Use Of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) In Patients With Rare Cause Of Nephrotic Syndrome Published In Transplantation

- First analysis to evaluate H.P. Acthar Gel for focal segmental glomerular sclerosis (FSGS) in kidney transplant recipients -

Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy

Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy

-- Drug being evaluated for improved functional outcomes and survival rates for patients resuscitated after a cardiac arrest --

Mallinckrodt To Present At 37th Annual J.P. Morgan Healthcare Conference

Mallinckrodt To Present At 37th Annual J.P. Morgan Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Dec. 17, 2018 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Jan.

MNK February 2019 Options Begin Trading

MNK February 2019 Options Begin Trading

Investors in Mallinckrodt plc saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.

Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter For Abuse-Deterrent, Immediate-Release Reformulation Of Roxicodone® (Oxycodone Hydrochloride)

Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter For Abuse-Deterrent, Immediate-Release Reformulation Of Roxicodone® (Oxycodone Hydrochloride)

STAINES-UPON-THAMES, United Kingdom, Dec. 12, 2018 /PRNewswire/ -- SpecGx LLC, a subsidiary of Mallinckrodt plc (NYSE: MNK) that operates its Specialty Generics business, announced today that it has received a Complete Response Letter from the U.

Mallinckrodt Plans Spin-Off Of Specialty Generics Business To Shareholders

Mallinckrodt Plans Spin-Off Of Specialty Generics Business To Shareholders

-- Transaction expected to create two differentiated pharmaceutical companies with scale - One focused on innovative specialty pharmaceutical brands; One with a portfolio of niche specialty generic products, active pharmaceutical ingredients (APIs), and non-promoted brands including the AMITIZA® product --

Mallinckrodt To Present At BMO Prescriptions For Success Healthcare Conference

Mallinckrodt To Present At BMO Prescriptions For Success Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Nov. 12, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, Dec.

Mallinckrodt Presents Terlipressin Clinical Data At The Liver Meeting® 2018

Mallinckrodt Presents Terlipressin Clinical Data At The Liver Meeting® 2018

- In Post-Hoc Pooled Analysis of North American Studies, Investigational Agent Terlipressin Associated With Improvement in Survival in Patients with Hepatorenal Syndrome Type 1 with Low Baseline Mean Arterial Pressure -

Mallinckrodt Earns International Standard ISO 13485:2016 And Medical Device Single Audit Program (MDSAP) Certifications For INOmax® DSIR® Plus Nitric Oxide Delivery Systems

Mallinckrodt Earns International Standard ISO 13485:2016 And Medical Device Single Audit Program (MDSAP) Certifications For INOmax® DSIR® Plus Nitric Oxide Delivery Systems

-- Achievements Indicate Mallinckrodt Meets Standards and Regulations Among the Most Comprehensive for Medical Device Quality Management Systems --

Mallinckrodt Plc Reports Third Quarter 2018 Results And Raises Earnings Guidance For 2018

Mallinckrodt Plc Reports Third Quarter 2018 Results And Raises Earnings Guidance For 2018

-- Net sales of $640.0 million, up 6.6%, or 6.7% on a constant-currency basis --

Leading Hepatorenal Expert Joins Mallinckrodt's Scientific Advisory Council

Leading Hepatorenal Expert Joins Mallinckrodt's Scientific Advisory Council

STAINES-UPON-THAMES, United Kingdom, Nov. 2, 2018 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the addition of a new member to its Scientific Advisory Council (SAC).

December 14th Options Now Available For Mallinckrodt (MNK)

December 14th Options Now Available For Mallinckrodt (MNK)

Investors in Mallinckrodt plc saw new options begin trading today, for the December 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new December 14th contracts and identified one put and one call contract of particular interest.

First Patient Screened In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, Or Panuveitis

First Patient Screened In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, Or Panuveitis

STAINES-UPON-THAMES, United Kingdom, Oct. 26, 2018 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed screening of the first patient in the company's Phase 4, multi-center, multiple-dose, open...

Mallinckrodt And The Lupus Foundation Of America Present Data From Survey Of Over 1,500 Individuals With Self-Reported Lupus At The 2018 American College Of Rheumatology/Association Of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting

Mallinckrodt And The Lupus Foundation Of America Present Data From Survey Of Over 1,500 Individuals With Self-Reported Lupus At The 2018 American College Of Rheumatology/Association Of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting

-- Study finds individuals with lupus experience a high disease flare burden and as a result engage in preventive and treatment measures --

TheStreet Quant Rating: D (Sell)